Equities analysts expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will announce sales of $1.10 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Xeris Pharmaceuticals’ earnings, with estimates ranging from $890,000.00 to $1.30 million. Xeris Pharmaceuticals reported sales of $800,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 37.5%. The business is expected to announce its next earnings results on Wednesday, March 4th.

On average, analysts expect that Xeris Pharmaceuticals will report full year sales of $1.83 million for the current financial year, with estimates ranging from $1.46 million to $2.20 million. For the next year, analysts anticipate that the company will post sales of $22.69 million, with estimates ranging from $22.17 million to $23.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last posted its earnings results on Thursday, November 7th. The company reported ($1.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million.

A number of research firms have recently weighed in on XERS. Mizuho restated a “buy” rating and issued a $22.00 target price on shares of Xeris Pharmaceuticals in a report on Thursday, November 21st. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, Zacks Investment Research upgraded Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 16th.

Shares of XERS stock traded down $0.06 during trading hours on Monday, reaching $6.13. The company had a trading volume of 59,424 shares, compared to its average volume of 319,361. Xeris Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $17.62. The company has a debt-to-equity ratio of 1.33, a current ratio of 5.96 and a quick ratio of 5.96. The business has a fifty day simple moving average of $7.61 and a 200-day simple moving average of $9.50. The company has a market cap of $167.13 million, a price-to-earnings ratio of -1.23 and a beta of -0.48.

In other Xeris Pharmaceuticals news, insider Paul R. Edick purchased 17,935 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $153,344.25. Following the completion of the acquisition, the insider now owns 172,935 shares of the company’s stock, valued at approximately $1,478,594.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Steven Prestrelski sold 10,000 shares of Xeris Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $5.50, for a total value of $55,000.00. Following the sale, the insider now owns 421,824 shares in the company, valued at $2,320,032. The disclosure for this sale can be found here. Company insiders own 7.43% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Bank of Montreal Can bought a new stake in shares of Xeris Pharmaceuticals in the second quarter valued at $26,000. Tower Research Capital LLC TRC acquired a new position in shares of Xeris Pharmaceuticals in the second quarter worth about $42,000. Marshall Wace North America L.P. acquired a new position in shares of Xeris Pharmaceuticals in the first quarter worth about $71,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Xeris Pharmaceuticals in the third quarter worth about $100,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Xeris Pharmaceuticals in the second quarter worth about $118,000. Institutional investors and hedge funds own 66.37% of the company’s stock.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Story: What is a stock split?

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.